Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)--added trial

Authors :: McMurray, John J.V.
Young, James B.
Dunlap, Mark E.
Granger, Christopher B.
Hainer, James
Michelson, Eric L.
Earle, Steven
Olofsson, Bertil
Ostergren, Jan
Yusuf, Salim
Swedberg, Karl
Pfeffer, Marc A.
Source :: American Heart Journal. May, 2006, Vol. 151 Issue 5, p985, 7 p.
Publication Year :: 2006

Subjects :: Angiotensin converting enzyme -- Research
Angiotensin converting enzyme -- Physiological aspects
Heart failure -- Research
Heart failure -- Care and treatment
Mortality -- Evaluation
Candesartan -- Research
Candesartan -- Physiological aspects
Health

Tools